Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.93 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.93 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.93 |
| ▸ | MAPT | P10636 | 1/20 | 0.93 |
| ▸ | BLM | P54132 | 1/20 | 0.93 |
| ▸ | MGLL | Q99685 | 1/20 | 0.93 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 0.93 |
| ▸ | CES1 | P23141 | 7/20 | 0.87 |
| ▸ | CES2 | O00748 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | F7 | P08709 | 1/20 | 0.64 |
| ▸ | F3 | P13726 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459981 | 1.00 | FAAH (0.93) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT | |
| SCHEMBL3679974 | 0.98 | FAAH (0.90) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT | |
| SCHEMBL3679976 | 0.98 | FAAH (0.90) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT | |
| SCHEMBL22195368 | 0.97 | FAAH (0.88) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT | |
| Arachidonyl Trifluoromethylketone SCHEMBL9880640 | 0.97 | FAAH (1.00) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT | |
| Arachidonyl Trifluoromethylketone SCHEMBL30426991 | 0.97 | FAAH (1.00) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT | |
| SCHEMBL24939095 | 0.93 | FAAH (1.00) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT | |
| SCHEMBL24938529 | 0.93 | FAAH (1.00) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT | |
| SCHEMBL8059738 | 0.93 | FAAH (1.00) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT | |
| SCHEMBL4085373 | 0.93 | FAAH (1.00) | FAAHPLA2G4AALDH1A1PLA2G4BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073476-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER BY REDUCING THE EXPRESSION AND/OR ACTIVITY OF PLA2G10 | YALE UNIVERSITY (US) | 2024-04-04 | — | — | WO | claimed |
| US-20230060937-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | SYNGENTA PARTICIPATIONS AG (CH) | 2023-03-02 | — | — | US | claimed |
| EP-3923962-A2 | GENE NETWORKS THAT MEDIATE REMYELINATION OF THE HUMAN BRAIN | University of Rochester (US) | 2021-12-22 | — | — | EP | claimed |
| EP-3899016-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | Syngenta Participations AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020167822-A2 | GENE NETWORKS THAT MEDIATE REMYELINATION OF THE HUMAN BRAIN | UNIVERSITY OF ROCHESTER (US) | 2020-08-20 | — | — | WO | claimed |
| WO-2020144192-A1 | USE OF ARACHIDONYL TRIFLUOROMETHYL KETONE | MOSAIQUES DIAGNOSTICS UND THERAPEUTICS AG (DE) | 2020-07-16 | — | — | WO | claimed |
| EP-3677259-A1 | USE OF ARACHIDONYL TRIFLUOROMETHYL KETONE | Mosaiques Diagnostics And Therapeutics AG (DE) | 2020-07-08 | — | — | EP | claimed |
| WO-2020131788-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | SYNGENTA PARTICIPATIONS AG (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-3547825-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | Syngenta Participations AG (CH) | 2019-10-09 | — | — | EP | claimed |
| US-9999603-B2 | Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer | THE PENN STATE RESEARCH FOUNDATION (US) | 2018-06-19 | — | — | US | claimed |
| US-20060058225-A1 | Used of inhibitors of phospholipase a2 for the treatment, prevention or diagnosis of neural inflammatory or demyelinating disease | MCGILL UNIVERSITY | 2006-03-16 | — | — | US | claimed |
| EP-1294411-A4 | A NOVEL TREATMENT FOR COUGH | UNIV CALIFORNIA (US) | 2006-02-01 | — | — | EP | claimed |
| WO-2005107766-A1 | PHOSPHOLIPASE INHIBITORS LOCALIZED IN THE GASTROINTESTINAL LUMEN | ILYPSA, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-20050244367-A1 | Phospholipase inhibitors localized in the gastrointestinal lumen | ILYPSA, INC. (US) | 2005-11-03 | — | — | US | claimed |
| EP-1509247-A1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT, PREVENTION OR DIAGNOSIS OF NEURAL INFLAMMATORY OR DEMYELINATING DIESEASES | McGILL UNIVERSITY (CA) | 2005-03-02 | — | — | EP | claimed |
| WO-2003101487-A1 | USE OF INHIBITORS OF PHOSPHOLIPASE A2 FOR THE TREATMENT, PREVENTION OR DIAGNOSIS OF NEURAL INFLAMMATORY OR DEMYELINATING DISEASE | MCGILL UNIVERSITY (CA) | 2003-12-11 | — | — | WO | claimed |
| US-20030225011-A1 | Phospholipase A2 expression and activity and use thereof for diagnosis, prognostication, prevention and treatment of neural inflammatory and demyelinating disease | MCGILL UNIVERSITY (CA) | 2003-12-04 | — | — | US | claimed |
| EP-1294411-A1 | A NOVEL TREATMENT FOR COUGH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020035150-A1 | Novel treatment for cough | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2002-03-21 | — | — | US | claimed |
| WO-2001089589-A1 | A NOVEL TREATMENT FOR COUGH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035150-A1 | Novel treatment for cough | CNR1, CNR2, TRPV1 | FAAH 14/4885PLA2G4A 1002/4885ALDH1A1 3682/4885 |
| US-20050244367-A1 | Phospholipase inhibitors localized in the gastrointestinal lumen | PNLIP, PLA2G2E, PLA2G4B | FAAH 142/4885PLA2G4A 5/4885ALDH1A1 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.